Washington, D.C. 20549






Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 19, 2013



Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)




Delaware   000-50679   77-0487658
(State or other jurisdiction
of incorporation)


File Number)

  (I.R.S. Employer
Identification Number)

149 Commonwealth Drive

Menlo Park, CA 94025

(Address of principal executive offices, with zip code)

(650) 327-3270

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former, address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 19, 2013, Steven Lo, Vice President, Commercial Operations of Corcept Therapeutics Incorporated (the “Company”), was promoted to the position of Senior Vice President and Chief Commercial Officer of the Company, effective immediately.

Mr. Lo, age 46, joined the Company as Vice President, Commercial Operations in September 2010. Mr. Lo has more than 19 years of commercial experience in the pharmaceutical and biotechnology industry. From 1997 to 2010, Mr. Lo held various positions in marketing, sales and managed markets at Genentech, Inc., a biotechnology company that became a member of the Roche Group in March 2009, most recently as Franchise Head, leading that company’s endocrinology marketing and sales organization. Mr. Lo received his B.S. degree from the University of California, Davis and his Master of Health Administration from the University of Southern California.

In connection with Mr. Lo’s promotion, the board of directors of the Company approved an increase in Mr. Lo’s annual base salary to $385,000, effective immediately, and Mr. Lo was awarded an additional stock option to purchase 200,000 shares of the Company’s common stock. The option award will vest in equal monthly installments at the rate of 2.08334% per month over forty-eight (48) months, commencing on the first monthly anniversary of November 19, 2013. The exercise price per share for the option award is $1.92, the closing price of the Company’s common stock on The NASDAQ Stock Exchange on November 19, 2013.




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



/s/ G. Charles Robb

  Name: G. Charles Robb
  Title:   Chief Financial Officer

Date: November 25, 2013